Health Condition 1: L501- Idiopathic urticaria
Conditions
Interventions
Intervention1: Cognitive behavioral therapy, intramuscular injection of triamcinolone acetonide: Cognitive behavioral therapy 30 minutes session once a month + intramuscular injection of triamcinolone
Sponsors
Department of Science and Technology Science and Engineering Research Board DSTSERB
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria for cases (serum (154 cases) and skin (20 samples): 1. Consecutive consenting patients of both gender aged 18-60 years, attending the â??Chronic Urticaria clinicâ?? of the dermatology OPD of JIPMER diagnosed with chronic spontaneous urticaria, characterized by the presence of continuous or recurrent weals with or without angioedema of greater than 6 weeks duration. Inclusion criteria for controls (serum)(154 controls): 1. Age and gender matched healthy subjects Inclusion criteria for controls (skin): (20 samples) 1.Discarded skin samples obtained for split thickness graft for treatment of ulcers
Exclusion criteria
Exclusion criteria: Exclusion criteria for both cases (154 cases) and controls (154 controls): 1.Subjects not on any medication for the past three months prior to recruitment other than antihistamines 2.Physical urticaria and urticarial vasculitis 3.Pregnant and lactating women 4.Pre-existing endocrine disorders 5.Pre-existing psychiatric illness 6.Pre-existing chronic illness like diabetes, hypertension, hepatic and renal disease, connective tissue diseases, malignancies 7.Other inflammatory skin diseases like psoriasis, lichen planus, vitiligo, pityriasis rubra pilaris, erythroderma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effectiveness of intervention among CSU patients (154) on clinical outcome: 1.stress scores (Daily Hassles and Uplifts Scale-Revised (DHUS-R);Presumptive Stressful Life Events Scale (PSLE);Perceived stress scale (PSS)-10 item); 2.disease activity and disease severity scores (Urticaria activity score (sum score of 7 consecutive days) (UAS 7);Urticaria severity score (USS);Urticaria control test (UCT; 3.quality of life scores(Chronic urticaria- Quality of life (CU-Q2oL); 4. medication usageTimepoint: At recruitment; Follow up at 1,2,3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Autoreactivity among cases with CSU(154) 1.Autologous serum skin test (ASST) 2.Basophil histamine release assay (BHRA) 3.Specific IgG autoantibodies against FcÉ?R1αTimepoint: At recruitment;Comparison of cutaneous neuropeptide expression between cases (20) and controls (20): 1. immunohistchemistry of NGF, SP , CGRP, Neuropeptide YTimepoint: At recruitment;Comparison of stress scores between cases (154) and controls (154) 1.Daily Hassles and Uplifts Scale-Revised (DHUS-R 2.Presumptive Stressful Life Events Scale (PSLE) 3.Perceived stress scale (PSS)-10 item)Timepoint: At recruitment;Comparison of the following serum levels between cases (154) and controls (154): 1.stress hormones and central HPA axis activity:CRH, ACTH, cortisol, DHEAS, Prolactin, DHEAS/Cortisol ratio 2.inflammatory cytokines:IL-6, IL-18, hs CRP, VEGF 3.neuropeptides: NGF, SP , CGRP, Neuropeptide YTimepoint: At recruitment;Comparison of expression of cutaneous HPA axis activity between cases (20)and controls (20): 1.m RNA expression of CRH, CRH-R1, ACTH, hydroxysteroid 11 beta dehydrogenase 1 and 2 (HSD11B1, HSD11B2); glucocorticoid receptors - nuclear receptor subfamily 3, group C, member 1a (NR3C1a) and b (NR3C1b) 2.immunohistochemistry of CRH, CRH-R1Timepoint: At recruitment;Effectiveness of intervention among CSU patients (154) on serum levels of: 1.stress hormones and central HPA axis activity:CRH, ACTH, cortisol, DHEAS, Prolactin, DHEAS/Cortisol ratio 2.inflammatory cytokines:IL-6, IL-18, hs CRP, VEGF 3.neuropeptides: NGF, SP , CGRP, Neuropeptide YTimepoint: At recruitment; Follow up at 3 months | — |
Countries
India
Contacts
Public ContactDr M Malathi
Jawaharlal Institute of Postgraduate Medical Education and Research
Outcome results
None listed